COVID-19
Conditions
Brief summary
To measure the frequency of persistent liver dysfunction (raised liver enzymes, serum albumin, prothrombin time, etc) in recovered COVID -19 patients. To compare the hepatic manifestations in post COVID -19 patients with and without liver disease
Detailed description
The digestive tract, particularly the liver, has recently been reported to be affected by SARS-CoV-2. Although abnormal liver enzymes were regularly described as an extra-pulmonary clinical feature, and almost one half of patients experienced grades of hepatic injury. liver damage in patients with SARS infections was primarily manifested in the mild and moderate elevation of alanine and/or aspartate aminotransferases (ALT and AST) with some degree of hypoalbuminemia and hyperbilirubinemia during the early stage of the illness.
Interventions
DIAGNOSTIC_TESTliver function , prothrombin time , INR , US .
analytic
Sponsors
Assiut University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Inclusion criteria
* Patients previously diagnosed by COVID 19 eg : PCR and / or HRCT chest, lab of more than 1 month duration.
Exclusion criteria
* Patients less than 18 y. * Patients with acute COVID 19.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| to evaluate the long term effect of COVID 19 on the liver | 1 month | to evaluate the changes in liver function (bilirubin ,liver enzymes , albumin , prothrombin time and INR in patients post COVID\_19 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| : Effect of COVID 19 on diseased liver | 1 month | to evaluate the changes in liver function(bilirubin , liver enzymes , albumin , prothrombin time , INR) in cirrhotic post COVID\_19 |
Countries
Egypt
Outcome results
None listed